AKEBIA THERAPEUTICS ($AKBA) posted quarterly earnings results for Q4 2025 on Thursday, February 26th. The company reported earnings of -$0.05 per share, missing estimates of -$0.01 by $0.04. The company also reported revenue of $57,620,000, beating estimates of $49,340,664 by $8,279,336.
You can see Quiver Quantitative's $AKBA stock page to track data on insider trading, hedge fund activity, congressional trading, and more.
AKEBIA THERAPEUTICS Insider Trading Activity
AKEBIA THERAPEUTICS insiders have traded $AKBA stock on the open market 15 times in the past 6 months. Of those trades, 0 have been purchases and 15 have been sales.
Here’s a breakdown of recent trading of $AKBA stock by insiders over the last 6 months:
- JOHN P. BUTLER (CEO and President) has made 0 purchases and 4 sales selling 341,305 shares for an estimated $474,413.
- NICHOLAS GRUND (Chief Commercial Officer) has made 0 purchases and 2 sales selling 84,829 shares for an estimated $117,912.
- CAROLYN M. RUCCI (SVP, Chief Legal Officer) has made 0 purchases and 3 sales selling 69,772 shares for an estimated $96,983.
- STEVEN KEITH BURKE (SVP, Chief Medical Officer) has made 0 purchases and 3 sales selling 67,658 shares for an estimated $94,044.
- RICHARD C MALABRE (SVP, Chief Accounting Officer) has made 0 purchases and 2 sales selling 49,524 shares for an estimated $68,838.
- ERIK OSTROWSKI (SVP, CFO, CBO & Treasurer) sold 34,951 shares for an estimated $48,581
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
AKEBIA THERAPEUTICS Hedge Fund Activity
We have seen 86 institutional investors add shares of AKEBIA THERAPEUTICS stock to their portfolio, and 97 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- MORGAN STANLEY removed 3,086,385 shares (-71.5%) from their portfolio in Q4 2025, for an estimated $4,969,079
- GOLDMAN SACHS GROUP INC added 2,938,624 shares (+166.2%) to their portfolio in Q4 2025, for an estimated $4,731,184
- MPM BIOIMPACT LLC removed 2,889,125 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $4,651,491
- UBS GROUP AG removed 2,774,699 shares (-76.1%) from their portfolio in Q4 2025, for an estimated $4,467,265
- FRANKLIN RESOURCES INC removed 2,498,569 shares (-93.2%) from their portfolio in Q4 2025, for an estimated $4,022,696
- AFFINITY ASSET ADVISORS, LLC removed 2,450,000 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $3,944,500
- GREAT POINT PARTNERS LLC removed 1,985,915 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $5,421,547
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
AKEBIA THERAPEUTICS Analyst Ratings
Wall Street analysts have issued reports on $AKBA in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- BTIG issued a "Buy" rating on 02/25/2026
To track analyst ratings and price targets for AKEBIA THERAPEUTICS, check out Quiver Quantitative's $AKBA forecast page.
AKEBIA THERAPEUTICS Price Targets
Multiple analysts have issued price targets for $AKBA recently. We have seen 3 analysts offer price targets for $AKBA in the last 6 months, with a median target of $4.0.
Here are some recent targets:
- Julian Harrison from BTIG set a target price of $4.0 on 02/25/2026
- Matthew Caufield from HC Wainwright & Co. set a target price of $6.0 on 02/06/2026
- Allison Bratzel from Piper Sandler set a target price of $4.0 on 02/06/2026
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
